Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
BOTA's Cash to Debt is ranked higher than
79% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. BOTA: No Debt )
BOTA' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.80
BOTA's Equity to Asset is ranked higher than
83% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BOTA: 0.80 )
BOTA' s 10-Year Equity to Asset Range
Min: 0.25   Max: 0.85
Current: 0.8

0.25
0.85
Interest Coverage No Debt
BOTA's Interest Coverage is ranked higher than
79% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BOTA: No Debt )
BOTA' s 10-Year Interest Coverage Range
Min: 1   Max: 9999.99
Current: No Debt

1
9999.99
F-Score: 3
Z-Score: 2.02
M-Score: 9.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -25.22
BOTA's Operating margin (%) is ranked higher than
78% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. BOTA: -25.22 )
BOTA' s 10-Year Operating margin (%) Range
Min: -171.38   Max: 49.83
Current: -25.22

-171.38
49.83
Net-margin (%) -24.52
BOTA's Net-margin (%) is ranked higher than
78% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. BOTA: -24.52 )
BOTA' s 10-Year Net-margin (%) Range
Min: -178.54   Max: 44.58
Current: -24.52

-178.54
44.58
ROE (%) -17.95
BOTA's ROE (%) is ranked higher than
79% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. BOTA: -17.95 )
BOTA' s 10-Year ROE (%) Range
Min: -57.58   Max: 79.12
Current: -17.95

-57.58
79.12
ROA (%) -14.18
BOTA's ROA (%) is ranked higher than
79% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. BOTA: -14.18 )
BOTA' s 10-Year ROA (%) Range
Min: -36.83   Max: 39.15
Current: -14.18

-36.83
39.15
ROC (Joel Greenblatt) (%) -199.45
BOTA's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. BOTA: -199.45 )
BOTA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2866.96   Max: 82.24
Current: -199.45

-2866.96
82.24
Revenue Growth (%) -22.60
BOTA's Revenue Growth (%) is ranked higher than
67% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. BOTA: -22.60 )
BOTA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 5
Current: -22.6

0
5
EBITDA Growth (%) 93.50
BOTA's EBITDA Growth (%) is ranked higher than
99% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. BOTA: 93.50 )
BOTA' s 10-Year EBITDA Growth (%) Range
Min: -77.1   Max: 114.1
Current: 93.5

-77.1
114.1
» BOTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

BOTA Guru Trades in Q4 2013

Jim Simons 314,805 sh (-1.11%)
» More
Q1 2014

BOTA Guru Trades in Q1 2014

George Soros 39,500 sh (New)
Jim Simons 320,905 sh (+1.94%)
» More
Q2 2014

BOTA Guru Trades in Q2 2014

Jim Simons 321,105 sh (+0.06%)
George Soros Sold Out
» More
Q3 2014

BOTA Guru Trades in Q3 2014

Jim Simons 349,605 sh (+8.88%)
» More
» Details

Insider Trades

Latest Guru Trades with BOTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out $2.36 - $6.08 $ 2.4-37%0
George Soros 2014-03-31 New Buy$4.19 - $6.98 $ 2.4-57%39500
George Soros 2011-09-30 Sold Out 0.0014%$9.93 - $34.49 $ 2.4-83%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.10
BOTA's P/B is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. BOTA: 1.10 )
BOTA' s 10-Year P/B Range
Min: 0.8   Max: 10.25
Current: 1.1

0.8
10.25
P/S 1.40
BOTA's P/S is ranked higher than
98% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. BOTA: 1.40 )
BOTA' s 10-Year P/S Range
Min: 1.06   Max: 25.86
Current: 1.4

1.06
25.86
PFCF 7.30
BOTA's PFCF is ranked higher than
99% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BOTA: 7.30 )
BOTA' s 10-Year PFCF Range
Min: 3.4   Max: 31.82
Current: 7.3

3.4
31.82
EV-to-EBIT -1.77
BOTA's EV-to-EBIT is ranked higher than
74% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BOTA: -1.77 )
BOTA' s 10-Year EV-to-EBIT Range
Min: -112.7   Max: 17.2
Current: -1.77

-112.7
17.2
Current Ratio 3.94
BOTA's Current Ratio is ranked higher than
70% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. BOTA: 3.94 )
BOTA' s 10-Year Current Ratio Range
Min: 1.35   Max: 26.34
Current: 3.94

1.35
26.34
Quick Ratio 3.94
BOTA's Quick Ratio is ranked higher than
71% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. BOTA: 3.94 )
BOTA' s 10-Year Quick Ratio Range
Min: 0.76   Max: 26.34
Current: 3.94

0.76
26.34

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.10
BOTA's Price/Net Cash is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. BOTA: 2.10 )
BOTA' s 10-Year Price/Net Cash Range
Min: 1.19   Max: 72.7
Current: 2.1

1.19
72.7
Price/Net Current Asset Value 2.10
BOTA's Price/Net Current Asset Value is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. BOTA: 2.10 )
BOTA' s 10-Year Price/Net Current Asset Value Range
Min: 1.19   Max: 98.26
Current: 2.1

1.19
98.26
Price/Tangible Book 1.10
BOTA's Price/Tangible Book is ranked higher than
98% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. BOTA: 1.10 )
BOTA' s 10-Year Price/Tangible Book Range
Min: 1.02   Max: 10.02
Current: 1.1

1.02
10.02
Price/DCF (Projected) 0.60
BOTA's Price/DCF (Projected) is ranked higher than
100% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BOTA: 0.60 )
BOTA' s 10-Year Price/DCF (Projected) Range
Min: 0.57   Max: 19.81
Current: 0.6

0.57
19.81
Price/Median PS Value 0.20
BOTA's Price/Median PS Value is ranked higher than
98% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. BOTA: 0.20 )
BOTA' s 10-Year Price/Median PS Value Range
Min: 0.06   Max: 4.39
Current: 0.2

0.06
4.39
Earnings Yield (Greenblatt) -56.50
BOTA's Earnings Yield (Greenblatt) is ranked higher than
50% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. BOTA: -56.50 )
BOTA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -56.5   Max: 46687.3
Current: -56.5

-56.5
46687.3
Forward Rate of Return (Yacktman) -92.55
BOTA's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 15.36 vs. BOTA: -92.55 )
BOTA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -43.7   Max: 71.5
Current: -92.55

-43.7
71.5

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:NB1N.Germany,
Biota Pharmaceuticals Inc was incorporated in Delaware since 1969. It is a clinical stage, biopharmaceutical company, engaged in the discovery and development of novel products to treat serious and potentially life-threatening infectious diseases. The Company's products in development are NicVAX [Nicotine Conjugate Vaccine], a proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Its research and development facilities are located in Melbourne, Australia and Oxford, United Kingdom.
» More Articles for BOTA

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: VCRA, CLUB, ARGS, ONTX, BOTA Jun 08 2014 

More From Other Websites
BIOTA PHARMACEUTICALS, INC. Financials Nov 15 2014
BIOTA PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Nov 12 2014
BIOTA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 10 2014
BIOTA PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 07 2014
Biota Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results Nov 07 2014
Q1 2015 Biota Pharmaceuticals Inc Earnings Release - Before Market Open Nov 07 2014
Biota Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results Nov 07 2014
Biota Pharmaceuticals to Host Conference Call to Report First Quarter Financial Results on November... Oct 28 2014
Biota Pharmaceuticals to Host Conference Call to Report First Quarter Financial Results on November... Oct 28 2014
BIOTA PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Oct 01 2014
BIOTA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Sep 30 2014
3 Biotech Stocks Under $10 to Trade for Breakouts Sep 26 2014
Biota Pharmaceuticals Reports Fourth Quarter and Fiscal Year-End 2014 Financial Results and... Sep 26 2014
Biota Pharmaceuticals Announces Changes to Management and Board of Directors Sep 26 2014
[video] What To Watch On Wall Street for Friday, September 26th 2014 Sep 25 2014
BIOTA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 01 2014
Midday movers: Chevron, Clorox, Harley-Davidson & more Aug 01 2014
Biota's lead drug fails mid-stage study, shares slump Aug 01 2014
BIOTA ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Biota... Aug 01 2014
Biota's influenza drug fails in mid-stage study Aug 01 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK